q1 non-gaap earnings per share $1.29.
q1 revenue rose 13 percent to $44 billion.
reaffirms fy non-gaap earnings per share view $5.60 to $5.90.
fy22 non-gaap earnings per share guidance reaffirmed, long-term financial targets announced.
board of directors approved a 3-year authorization to repurchase up to an additional $3 billion of cardinal health common shares.
first-quarter revenue for pharmaceutical segment increased 13% to $39.8 billion.
expectation that we will see greater inflationary pressures in medical segment for remainder of year.
